NPG-2044 is under clinical development by Novita Pharmaceuticals and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NPG-2044’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NPG-2044 overview
NPG-2044 is under development for the treatment of solid tumors including ovarian cancer, endometrial cancer, uterine cancer, fallopian tube cancer, non-muscle invasive bladder cancer, esophageal squamous cell carcinoma (ESCC), squamous cell carcinoma (ESCC), oropharyngeal squamous cell carcinoma (OPSCC), cervical cancer, vulvar cancer, vaginal cancer, triple-negative breast cancer, unspecified infectious disease, thyroid cancer, hematological malignancies, neurological degenerative diseases. It is a small molecule administered through oral route. It acts by targeting fascin protien. It is a new molecular entity (NME).
It was under development for the treatment of colon cancer, esophageal cancer, lymphoma, metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer, metastatic lung cancer, metastatic liver cancer, metastatic ovarian cancer.
Novita Pharmaceuticals overview
Novita Pharmaceuticals is developing first-in-class drugs to prevent and treat cancer metastasis as well as to boost anti-cancer immune responses. The company is headquartered in New York City, New York, the US.
For a complete picture of NPG-2044’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
